肌层浸润性膀胱癌新辅助化疗后最佳病理缓解的定义:全球多中心协作结果
该研究纳入10个国际中心625例接受新辅助化疗(NAC)后根治性膀胱切除术(RC)时达到<ypT2N0的肌层浸润性膀胱癌(MIBC)患者,评估不同病理缓解程度的复发风险。结果显示ypT0、纯ypTis、ypTa±ypTis和ypT1±ypTis的5年累积复发率分别为9%、16%、29%和30%,ypTa±Tis和ypT1±Tis复发风险显著增高。作者提出最佳病理缓解应定义为ypT0N0/ypTisN0,ypTaN0或ypT1N0患者可考虑辅助治疗试验。
要点
- NAC后RC时ypT0N0/ypTisN0可定义为最佳病理缓解。
- ypTa±Tis和ypT1±Tis患者5年复发率约29%-30%,风险显著增高。
- ypTaN0或ypT1N0患者可能是辅助治疗临床试验的候选人群。
核心结论
- 提出NAC后最佳病理缓解应定义为RC时达到ypT0N0/ypTisN0。
- ypTaN0或ypT1N0(伴或不伴Tis)患者复发风险显著更高,可能适合辅助治疗试验。
研究设计与样本
- 国际多中心回顾性协作研究,纳入10个中心因cT2-4aN0-1 MIBC接受NAC并在RC时达到<ypT2N0的患者625例。
- 主要结局为局部或远处复发时间,采用Kaplan-Meier和Cox比例风险回归分析。
主要发现
- ypT0、纯ypTis、ypTa±ypTis和ypT1±ypTis分别占58.1%、20.0%、7.6%和14.2%。
- 5年累积复发率分别为9%、16%、29%和30%。
- 与ypT0相比,ypTa±Tis复发风险HR 3.20(95%CI 1.40-7.30),ypT1±Tis复发风险HR 4.03(95%CI 2.13-7.63)。
- 纯ypTis复发风险HR 1.66(95%CI 0.82-3.38),与复发无显著关联。
- NAC方案与复发无显著关联:ddMVAC HR 1.59(95%CI 0.55-4.56),MVAC HR 1.18(95%CI 0.25-5.54),参照GC。
关键数值与推荐
- 最佳病理缓解定义为RC时达到ypT0N0/ypTisN0。
- ypTa±Tis和ypT1±Tis患者复发风险显著增高,HR分别为3.20和4.03。
临床怎么用
- RC后病理为ypT0N0或ypTisN0可视为最佳缓解,复发风险较低。
- ypTaN0或ypT1N0(伴或不伴Tis)患者应加强随访,并考虑纳入辅助治疗临床试验。
局限性
- 回顾性多中心设计可能存在选择偏倚和混杂。
- 仅纳入达到<ypT2N0的患者,未比较≥ypT2N0人群。
- NAC方案与复发关联的置信区间较宽,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate outcomes of patients achieving a post-treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) to identify an optimal definition of pathological response. PATIENTS AND METHODS: Patients from 10 international centres who underwent NAC for cT2-4aN0-1 MIBC and achieved <ypT2N0 disease at RC were included. The primary outcome was time to recurrence, either local or distant. Kaplan-Meier and Cox proportional hazards regression were used to evaluate associations between clinicopathological variables and outcomes. RESULTS: A total of 625 patients were included. The median age was 66 years and 80% were male. Gemcitabine and cisplatin (GC, 56%) and methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)/dose-dense (dd)MVAC (32%) were the most common NAC regimens. ypT0, pure ypTis, ypTa ±ypTis and ypT1 ± ypTis were attained in 58.1%, 20.0%, 7.6% and 14.2% of patients, respectively. The cumulative incidence of recurrence at 5 years was 9%, 16%, 29% and 30%, respectively. Pathological stage was prognostic for recurrence, with ypTa ± Tis (hazard ratio [HR] 3.20, 95% confidence interval [CI] 1.40-7.30) and ypT1 ± Tis disease (HR 4.03, 95% CI 2.13-7.63) associated with a significantly higher recurrence risk. Pure ypTis (HR 1.66, 95% CI 0.82-3.38) and the type of NAC regimen (ddMVAC: HR 1.59, 95% CI 0.55-4.56; MVAC: HR 1.18, 9%% CI 0.25-5.54; reference: GC) were not associated with recurrence. CONCLUSION: We propose that optimal pathological response after NAC be defined as attainment of ypT0N0/ypTisN0 at RC. Patients with ypTaN0 or ypT1N0 disease (with or without Tis) at RC displayed a significantly higher risk of recurrence and may be candidates for trials investigating adjuvant therapy.
引用
- Ravi P, Pond GR, Diamantopoulos LN, et al. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 2021. PMID: 33909949. doi:10.1111/bju.15434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。